262 related articles for article (PubMed ID: 12037374)
1. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.
Thiyagarajan M
Pharmacology; 2002 Jul; 65(3):119-28. PubMed ID: 12037374
[TBL] [Abstract][Full Text] [Related]
2. The use of alpha-adrenoceptor antagonists in the pharmacological management of benign prostatic hypertrophy: an overview.
Hieble JP; Ruffolo RR
Pharmacol Res; 1996 Mar; 33(3):145-60. PubMed ID: 8880886
[TBL] [Abstract][Full Text] [Related]
3. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
[TBL] [Abstract][Full Text] [Related]
4. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
5. The concept of uroselectivity.
Andersson KE
Eur Urol; 1998; 33 Suppl 2():7-11. PubMed ID: 9556190
[TBL] [Abstract][Full Text] [Related]
6. Alpha-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia.
Cooper KL; McKiernan JM; Kaplan SA
Drugs; 1999 Jan; 57(1):9-17. PubMed ID: 9951948
[TBL] [Abstract][Full Text] [Related]
7. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
[TBL] [Abstract][Full Text] [Related]
8. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
9. Prostatic and extraprostatic alpha-adrenoceptors--contributions to the lower urinary tract symptoms in benign prostatic hyperplasia.
Andersson KE
Scand J Urol Nephrol Suppl; 1996; 179():105-11. PubMed ID: 8908675
[TBL] [Abstract][Full Text] [Related]
10. History and nomenclature of alpha1-adrenoceptors.
Langer SZ
Eur Urol; 1999; 36 Suppl 1():2-6. PubMed ID: 10438241
[TBL] [Abstract][Full Text] [Related]
11. The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia with α-blockers: focus on silodosin.
Fonseca J; Martins da Silva C
Clin Drug Investig; 2015 Feb; 35 Suppl 1():7-18. PubMed ID: 25708606
[TBL] [Abstract][Full Text] [Related]
12. Subtype selective alpha1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia.
Forray C; Noble SA
Expert Opin Investig Drugs; 1999 Dec; 8(12):2073-2094. PubMed ID: 11139841
[TBL] [Abstract][Full Text] [Related]
13. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS--implications for clinical practice.
Yassin A; Saad F; Hoesl CE; Traish AM; Hammadeh M; Shabsigh R
Andrologia; 2006 Feb; 38(1):1-12. PubMed ID: 16420236
[TBL] [Abstract][Full Text] [Related]
14. New strategies for inhibition of non-adrenergic prostate smooth muscle contraction by pharmacologic intervention.
Yu Q; Gratzke C; Wang Y; Wang X; Li B; Strittmatter F; Herlemann A; Wang R; Tamalunas A; Waidelich R; Stief CG; Hennenberg M
Prostate; 2019 May; 79(7):746-756. PubMed ID: 30811062
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
16. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia.
Nickel JC
Urology; 2003 Sep; 62(3 Suppl 1):34-41. PubMed ID: 12957198
[TBL] [Abstract][Full Text] [Related]
17. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
18. Adrenoceptor pharmacology: urogenital applications.
Ruffolo RR; Hieble JP
Eur Urol; 1999; 36 Suppl 1():17-22. PubMed ID: 10393468
[TBL] [Abstract][Full Text] [Related]
19. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
Jolliet P; Bourin M
Therapie; 1998; 53(1):61-6. PubMed ID: 9773101
[TBL] [Abstract][Full Text] [Related]
20. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
